The Somatic Genomic Medicine Challenge
Genome encodes functional and dysfunctional information not only in its main chapters of linear sequences and primary chemical modifications, also in its dynamic multi-dimensional structures, organizations, functional derivatives in aberrant orders, locations and shapes, such as poly-aneuploidy chromosomes, chromothripsis, chromoplexy, and large circular extrachromosome DNAs (ecDNA). Under the much broader general epigenomic scope, these previously undefined medically relevant yet highly heterogenous somatic cell signals, change the narratives of the book of life as we age, often got destroyed or altered during destructive sample prep (such as fragmentation or bund-factor stripping during conventional sequencing and mapping workflow), or diluted and lost in conventional bulk solution averaging analysis.
About US
Dimension Genomics Inc is a post-seed stage startup dedicated to the development of new generation of sub-cellular and sub-nuclear single molecule level platform technology, targeting high dimension analysis in somatic cancer and aging cells.
Founded by a team of passionate tech entrepreneurs who have previous experience taking an original idea from Princeton University labs all the way to IPO and commercial products launch that changed how people assemble, study, understand linear genome and diagnose diseases.
Majority of human sequencing data existing today are based on averaged consensus calls of millions of mixed cells and molecules as reduced and compressed representations of partial or under-phased "haploidy" genome (exomes, transcripts, or the 3-Billion-base genome).
The sample averaging "meatball" style data might be "ok-enough-approximation" of the diploid single zygote-derived static germline genome analysis, for newborn, population survey, ancestry or common inherited disorder purpose (albeit often one-time/"one-spit" revenue and begs for Trio study). These "meatball" data assumed majority data sets today for AI training.
For medical grade analysis, the ground truth should be ~3.055-Billion (Aneuploidy), ~6.2-Billion (diploid) to ~20-Billion plus nucleotides (poly-aneuploidy), in any given genome of our 7 ~ 37-trillion evolving somatic body cells.
Cancer and degenerative aging diseases are the inevitable consequence of somatic genomes' deterioration after a life-time error-prone genomic replications as cells divide and renew. As we age, 30 ~ 90% of somatic tumors have poly-aneuploidy cancer cells (PACCs) driving disease progression, including extreme cases of circular ecDNA-driven cancer relapses and drug-resistance development, in as high as 60% of aggressive cancers such as brain tumors and Small Cell Lung Cancers (SCLCs).
Highly dynamic, complex and heterogenous somatic cell genome analysis in clinical context presents challenges for the legacy bulk solution sample consensus workflow, stagnates medical genomics transformation if continuing to bring a "Germline Analysis Knife" to a chaotic high-entropy "Somatic Genome Gun Fight".
Our Mission
Armed with decades of unique experience in manipulating macromolecules within designed entropy-controlled microenvironments, we developed proprietary nanotech platform technologies that physically organize, enrich, and isolate targets at the level of single aberrant chromosome and its derivatives.
This approach reveals the diluted or lost earliest deleterious molecular deviations in patient samples with highest signal clarity, often obfuscated by sample averaging across heterogeneous, rapidly evolving somatic cell populations.
Our discretely selective sample analysis technology will differentiate from the traditional bottom-up fragment-tiling workflow as a top-down high-resolution guided dissecting approach, deconvolute the often minor yet critical "outliners" being collapsed or abandoned by algorithms, uncover foundational biomarkers in subclones of somatic cells at minimal residual level. The physically clean sample will finally cleanse and elevate high quality raw genomic data to be truly AI compatible and safe for medical use, with immediate clinical utility and market impact.
In the reality of personalized medicine, consensus is a hallucination. Precision and fidelity prevail over generative. When the stakes are life, as token prices continue to trend down, the unadulterated high quality raw genomic data is the sovereign.
For decades, we have been visiting genomic "steak house" but only served "meatballs" and now "prosciutto", time to expand that menu.
Applications
Cancer Relapse and Drug Resistance Risk Assessment
Our ecDNA ecView Technology and Service allow us to provide precisely and efficiently full spectrum ecDNA profiles for translational research and recurring malignancy assessment for new and in-remission patients.
Companion Dx for Enhanced Trial Stratification
Over 90% oncology trials collapse and billions lost each year, not because drugs lacking activities, but often due to poor understanding of cancer biological heterogeneity. Aberrant genome + ecDNA profiling service screens cancer cell sample fitness and potential drug resistance assessment in patient stratification to improve better enrollment of candidates
Drug Discovery
Leveraging aberrant genome + ecDNA technology and database to provide service for translational research, preclinical drug discovery, uses advanced molecular modeling and artificial intelligence to identify novel drug targets and accelerate the development of life-saving therapies.
Precision Medicine
Our accessible bioinformatics expertise and software tools enable analysis and interpretation of complex genomics data, providing insights into disease mechanisms and new therapeutic targets.
Our personalized genomic and ecDNA profile information leverages genomic and clinical data to help physicians for individualized treatment plans reference and guidance, improving patient outcomes and quality of life.
The Future for Somatic Cancer Genomics is DISCRETE
Join Us in Transforming Precision Oncology and Genome Aging Management
From bulk averages to single-molecule precision through nanotechnology
- unlocking “hidden Drivers” in cancer relapses detection, monitoring, and treatment."
We are always looking for medial AI, translational, clinical application development partnerships
Dimension Genomics Inc San Diego, California
